1-(苯并[d]恶唑-2-基)乙胺 | 177407-15-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 中文名称: 1-(苯并[d]恶唑-2-基)乙胺
• 中文别名: A-甲基-2-苯并噁唑甲胺
• 英文名称: 1-(1,3-benzoxazol-2-yl)ethanamine
• 英文别名: 1-(1-benz[d]oxazol-2-yl)ethanamine；1-(2-benzoxazolyl)ethylamine；1-(Benzo[d]oxazol-2-yl)ethanamine
• CAS: 177407-15-7
• 化学式: C₉H₁₀N₂O
• 分子量: 162.191
• InChiKey: RAMYOLVPQWSXTB-UHFFFAOYSA-N

物化性质

• 沸点：
  247.2±23.0 °C(Predicted)
• 密度：
  1.185

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  1-(苯并[d]恶唑-2-基)乙胺 在 copper(ll) sulfate pentahydrate 、 triflic azide 作用下， 以 甲醇 、 水 为溶剂， 反应 18.0h， 生成 2-(1-azidoethyl)benzo[d]oxazole
  参考文献：
  名称：

  Discovery and Extensive in Vitro Evaluations of NK-HDAC-1: A Chiral Histone Deacetylase Inhibitor as a Promising Lead

  摘要：

  Herein, further SAR studies of lead compound NSC746457 (Shen, J.; Woodward, R.; Kedenburg, J. P.; Liu, X. W.; Chen, M.; Fang, L. Y.; Sun; D. X.; Wang. P. G. J. Med. Chem. 2008, SI, 7417-7427) were performed, including the replacement of the trans-styryl moiety with a 2-substituted benzo-hetero aromatic ring and the introduction of a substituent onto the central methylene carbon. A promising chiral lead, S-(E)-3-(1-(1-(benzo[d]oxazol-2-yl)-2-methylpropyl)-1H-1,2,3-triazol-4-yl)-N-hydroxyacrylamide (12, NK-HDAC-1), was discovered and showed about 1 order of magnitude more potency than SAHA in both enzymatic and cellular assays. For the in vitro safety tests, NK-HDAC-1 was far less toxic to nontransformed cells than tumor cells and showed no significant inhibition activity against CYP-3A4. The pharmaceutical properties (LogD, solubility, liver micrsomal stability (t1/2), plasma stability (t1/2), and apparent permeability) strongly suggested that NK-HDAC-1 might be superior to SAHA in bioavailability and in vivo half-life.

  DOI：

  10.1021/jm201496g
• 作为产物：
  描述：

  2-(1-Benzooxazol-2-yl-ethyl)-isoindole-1,3-dione 在 一水合肼 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 1-(苯并[d]恶唑-2-基)乙胺
  参考文献：
  名称：

  脂肪酶催化动力学拆分立体选择性化学酶法合成对映体纯 1-（杂芳基）乙胺

  摘要：

  1-（杂芳基）乙胺家族的有效化学合成和酶动力学拆分已使用脂肪酶进行，脂肪酶负责制备高光学纯度的含氮化合物。因此，Candida antarctica 脂肪酶 B 型已被确定为立体选择性生产相应对映体富集的 (R)-乙酰胺和 (S)-胺的极好生物催化剂。在反应性和对映选择性方面观察到环中杂原子的类似作用，反应一天后获得具有优异对映纯度的苯并恶唑、苯并噻唑和苯并咪唑衍生物。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)

  DOI：

  10.1002/ejoc.200900150

文献信息

• [EN] LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA LYSYL OXYDASE-LIKE 2 ET UTILISATIONS DESDITS INHIBITEURS
  申请人：PHARMAKEA INC

  公开号：WO2018048930A1

  公开（公告）日：2018-03-15

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述了一种LOXL2抑制剂化合物，制备这种化合物的方法，包含这种化合物的药物组合物和药物，以及使用这种化合物治疗与LOXL2活性相关的疾病、疾病或紊乱的方法。
• Amino-acid amide derivatives, processes for preparing the same,
  申请人：Kumiai Chemical Industry Co. Ltd.

  公开号：US05789428A1

  公开（公告）日：1998-08-04

  The present invention provides an amino-acid amide derivative represented by the formula: ##STR1## (wherein R.sup.1 represents a C1.about.C6 alkyl group, a C3.about.C8 cycloalkyl group, or a phenyl group, R.sup.2 represents a hydrogen atom or a methyl group, X represents a halogen atom, a methyl group, a methoxy group, Y represents a C1.about.C6 alkyl group, A represents an oxygen atom, or a sulfur atom, and n represents 0 or an integer from 1 to 3), an agricultural or horticultural fungicide including an effective amount of the same, and a method for killing agriculturally or horticulturally harmful fungi which comprises a step of using a fungicidally effective amount of the amino-acid amide derivative. The present invention provides the amino-acid amide derivatives, which exhibit superior control of plant diseases such as late blight and downy mildew, and which are not harmful chemicals.

  本发明提供了一种氨基酸酰胺衍生物，其表示为以下式子：##STR1##（其中R.sup.1表示C1到C6烷基，C3到C8环烷基或苯基，R.sup.2表示氢原子或甲基，X表示卤素原子，甲基，甲氧基，Y表示C1到C6烷基，A表示氧原子或硫原子，n表示0或1到3的整数），以及包括其有效量的农业或园艺杀菌剂，以及用氨基酸酰胺衍生物的杀灭农业或园艺有害真菌的方法。本发明提供了这种氨基酸酰胺衍生物，其表现出对植物病害如晚疫病和霜霉病的优越控制，且不是有害化学物质。
• AMINO ACID AMIDE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AGROHORTICULTURAL FUNGICIDE, AND FUNGICIDAL METHOD
  申请人：Kumiai Chemical Industry Co., Ltd.

  公开号：EP0775696B1

  公开（公告）日：2000-07-19
• Stereoselective Chemoenzymatic Synthesis of Enantiopure 1-(Heteroaryl)ethanamines by Lipase-Catalysed Kinetic Resolutions
  作者：Sergio Alatorre-Santamaría、Vicente Gotor-Fernández、Vicente Gotor

  DOI：10.1002/ejoc.200900150

  日期：2009.5

  The efficient chemical synthesis and enzymatic kinetic resolution of a family of 1-(heteroaryl)ethanamines have been performed with lipases responsible for the preparation of nitrogenated compounds in high optical purity. Thus, Candida antarctica lipase type B has been identified as an excellent biocatalyst for the stereoselective production of the corresponding enantiomerically enriched (R)-acetamides

  1-（杂芳基）乙胺家族的有效化学合成和酶动力学拆分已使用脂肪酶进行，脂肪酶负责制备高光学纯度的含氮化合物。因此，Candida antarctica 脂肪酶 B 型已被确定为立体选择性生产相应对映体富集的 (R)-乙酰胺和 (S)-胺的极好生物催化剂。在反应性和对映选择性方面观察到环中杂原子的类似作用，反应一天后获得具有优异对映纯度的苯并恶唑、苯并噻唑和苯并咪唑衍生物。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)
• Discovery and Extensive <i>in Vitro</i> Evaluations of NK-HDAC-1: A Chiral Histone Deacetylase Inhibitor as a Promising Lead
  作者：Jingli Hou、Zhonghua Li、Qinghong Fang、Congran Feng、Hanwen Zhang、Weikang Guo、Huihui Wang、Guoxian Gu、Yinping Tian、Pi Liu、Ruihua Liu、Jianping Lin、Yi-kang Shi、Zheng Yin、Jie Shen、Peng George Wang

  DOI：10.1021/jm201496g

  日期：2012.4.12

  Herein, further SAR studies of lead compound NSC746457 (Shen, J.; Woodward, R.; Kedenburg, J. P.; Liu, X. W.; Chen, M.; Fang, L. Y.; Sun; D. X.; Wang. P. G. J. Med. Chem. 2008, SI, 7417-7427) were performed, including the replacement of the trans-styryl moiety with a 2-substituted benzo-hetero aromatic ring and the introduction of a substituent onto the central methylene carbon. A promising chiral lead, S-(E)-3-(1-(1-(benzo[d]oxazol-2-yl)-2-methylpropyl)-1H-1,2,3-triazol-4-yl)-N-hydroxyacrylamide (12, NK-HDAC-1), was discovered and showed about 1 order of magnitude more potency than SAHA in both enzymatic and cellular assays. For the in vitro safety tests, NK-HDAC-1 was far less toxic to nontransformed cells than tumor cells and showed no significant inhibition activity against CYP-3A4. The pharmaceutical properties (LogD, solubility, liver micrsomal stability (t1/2), plasma stability (t1/2), and apparent permeability) strongly suggested that NK-HDAC-1 might be superior to SAHA in bioavailability and in vivo half-life.